Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Immune Design's Total Stockholders Equity for the quarter that ended in Dec. 2018 was $92.01 Mil. Immune Design's Total Assets for the quarter that ended in Dec. 2018 was $100.96 Mil.
Therefore, Immune Design's Equity to Asset Ratio for the quarter that ended in Dec. 2018 was 0.91.
The historical rank and industry rank for Immune Design's Equity-to-Asset or its related term are showing as below:
IMDZ's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67 * Ranked among companies with meaningful Equity-to-Asset only.
Immune Design Equity-to-Asset Historical Data
The historical data trend for Immune Design's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Immune Design's Equity-to-Asset
For the Biotechnology subindustry, Immune Design's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immune Design's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immune Design's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Immune Design's Equity-to-Asset falls into.
Immune Design Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Immune Design's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Immune Design Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Immune Design's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Immune Design (Immune Design) Business Description
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMDZ has been successfully added to your 